Subscribe
The latest psychology and neuroscience discoveries.
My Account
  • Mental Health
  • Social Psychology
  • Cognitive Science
  • Psychopharmacology
  • Neuroscience
  • About
No Result
View All Result
PsyPost
PsyPost
No Result
View All Result
Home Exclusive Mental Health Depression

A single dose of psilocybin improves depression in treatment-resistant patients, but with adverse effects

by Beth Ellwood
December 27, 2022
in Depression, Psilocybin
(Photo credit: Adobe Stock)

(Photo credit: Adobe Stock)

Share on TwitterShare on Facebook
Stay on top of the latest psychology findings: Subscribe now!

A recent study published in the New England Journal of Medicine suggests that psilocybin therapy may offer therapeutic benefits for patients with treatment-resistant depression. When administered alongside psychological support, a 25 mg psilocybin dose reduced depression scores among treatment-resistant patients. However, adverse effects were reported, and further clinical trials are needed.

Clinical depression is typically treated with a combination of anti-depressant medication and psychotherapy. While most patients experience a reduction in symptoms with anti-depressants, a subset of people fail to respond to the medication. A case that does not respond to two courses of anti-depressants is referred to as treatment-resistant depression.

Preliminary studies have suggested that psilocybin — a psychedelic compound found in certain species of mushrooms — may have antidepressant properties. In their recently-published study, researchers Guy M. Goodwin and his colleagues explored its potential to treat depression among people who are resistant to usual treatment.

“The potential of psychedelics in mental health has been investigated by scientists for many years, but only recently has research moved to larger scale studies,” explained Goodwin, the chief medical officer at COMPASS Pathways.

“These large trials are needed to demonstrate treatments are safe and effective, receive regulatory approvals, and get them to people who urgently need new options. We focus on areas of unmet need in mental health, for example treatment-resistant depression, which affects 100 million people globally.”

“We have just begun a phase 3 programme in treatment-resistant depression, which is the largest-ever clinical trial of psilocybin therapy globally, and we’re also studying COMP360 psilocybin therapy in post-traumatic stress disorder and anorexia nervosa.”

The researchers conducted a double-blind, randomized clinical trial among 233 patients diagnosed with treatment-resistant depression. The study was conducted at 22 sites in 10 different countries. For 3-6 weeks leading up to the study, participants tapered off any antidepressants they were taking and met with a therapist to prepare for the trial. Participants were then randomly assigned to receive either a 25 mg, a 10 mg, or a 1 mg dose of psilocybin. The 1 mg dose served as a control condition.

After the treatment, participants were followed for 12 weeks. The day after the treatment and one week after treatment, the participants attended therapist-led integration sessions to help them reflect on the psilocybin experience. Participants also completed assessments of depression over the phone at various time points throughout the study.

Goodwin and his team analyzed changes in participants’ depression scores, comparing the groups who received 25 mg and 10 mg of psilocybin to the control group. The results revealed that from baseline to week 3, the 25 mg group showed improvements in their depression scores that significantly exceeded changes in the 1 mg group. Change in depression scores was no different between the 10 mg and 1 mg groups.

“We saw positive results in a particularly difficult to treat type of depression – treatment-resistant depression – where patients have tried at least two antidepressant treatments without success,” Goodwin told PsyPost.

“Our study showed that after a single 25mg dose of COMP360 psilocybin therapy with psychological support, approximately 30% of patients were in remission at three weeks, and we saw effects lasting for up to three months.”

Notably, adverse events were reported in all groups, the most common being headaches, nausea, dizziness, and fatigue. Reports also included suicidal ideation and self-injurious behavior, and these events were more common among those who took 25 mg or 10 mg compared to 1 mg.

Limitations of the study include that the sample was not ethnically diverse, with 92% of participants being White. Additionally, the study did not assess whether participants could correctly guess which dose of psilocybin they received, which means that placebo effects cannot be entirely ruled out.

Overall, the findings suggest that a single dose of 25 mg of psilocybin — but not 10 mg — can improve depression symptoms among people with treatment-resistant depression when administered alongside therapy. Nevertheless, the adverse events are cause for concern, particularly the reports of worsening suicidality.

“We are about to start the world’s first ever phase 3 pivotal programme of psilocybin therapy in treatment-resistant depression,” Goodwin said. “Our phase 3 programme will seek to validate our phase 2b results published in the New England Journal of Medicine, and also investigate if a second dose of COMP360 psilocybin can increase rates of treatment response seen in the phase 2b study.”

The study, “Single-Dose Psilocybin for a Treatment-Resistant Episode of Major Depression”, was authored by G.M. Goodwin, S.T. Aaronson, O. Alvarez, P.C. Arden, A. Baker, J.C. Bennett, C. Bird, R.E. Blom, C. Brennan, D. Brusch, L. Burke, K. Campbell‑Coker, R. Carhart‑Harris, J. Cattell, A. Daniel, C. DeBattista, B.W. Dunlop, K. Eisen, D. Feifel, M.K. Forbes, H.M. Haumann, D.J. Hellerstein, A.I. Hoppe, M.I. Husain, L.A. Jelen, J. Kamphuis, J. Kawasaki, J.R. Kelly, R.E. Key, R. Kishon, S. Knatz Peck, G. Knight, M.H.B. Koolen, M. Lean, R.W. Licht, J.L. Maples‑Keller, J. Mars, L. Marwood, M.C. McElhiney, T.L. Miller, A. Mirow, S. Mistry, T. Mletzko‑Crowe, L.N. Modlin, R.E. Nielsen, E.M. Nielson, S.R. Offerhaus, V. O’Keane, T. Páleníček, D. Printz, M.C. Rademaker, A. van Reemst, F. Reinholdt, D. Repantis, J. Rucker, S. Rudow, S. Ruffell, A.J. Rush, R.A. Schoevers, M. Seynaeve, S. Shao, J.C. Soares, M. Somers, S.C. Stansfield, D. Sterling, A. Strockis, J. Tsai, L. Visser, M. Wahba, S. Williams, A.H. Young, P. Ywema, S. Zisook, and E. Malievskaia.

TweetSendScanShareSendPin4ShareShareShareShareShare

RELATED

Optimistic individuals are more likely to respond to SSRI antidepressants
Depression

Optimistic individuals are more likely to respond to SSRI antidepressants

May 19, 2025

People with depression who were more optimistic at the start of treatment—and whose optimism increased during treatment—were more likely to benefit from SSRIs, according to a recent study, raising the possibility of tailoring treatments based on psychological traits.

Read moreDetails
Inhaled DMT produces rapid and lasting antidepressant effects in treatment-resistant depression
Ayahuasca

Inhaled DMT produces rapid and lasting antidepressant effects in treatment-resistant depression

May 17, 2025

Vaporized DMT produced fast and lasting improvements in depression symptoms and suicidal ideation, according to a new phase 2a trial, highlighting its potential as a scalable, non-invasive alternative to conventional and long-acting psychedelic treatments for severe depression.

Read moreDetails
New research points to gut serotonin as a potential way to treat depression and anxiety
Depression

New research points to gut serotonin as a potential way to treat depression and anxiety

May 16, 2025

New research reveals that serotonin in the gut lining can reduce anxiety and depression symptoms in mice—without the side effects of traditional antidepressants—and may offer a safer alternative for treating mood disorders during pregnancy.

Read moreDetails
New research links postnatal depression to a disrupted oxytocin response during breastfeeding
Depression

New research links postnatal depression to a disrupted oxytocin response during breastfeeding

May 15, 2025

A new study finds that postnatal depression may impair the body’s hormonal response to breastfeeding. While oxytocin nasal spray boosted breast milk levels in healthy mothers, the same effect was not seen in those experiencing depressive symptoms after childbirth.

Read moreDetails
Stress-induced “fixated” eating patterns linked to dopamine disruption, study finds
Depression

New research links antidepressant effects of escitalopram to endocannabinoid system changes

May 12, 2025

In a rodent model of childhood adversity, escitalopram treatment during adolescence reduced signs of emotional distress. The study also found gene-level changes in the endocannabinoid system, pointing to a possible biological mechanism for the drug’s effectiveness.

Read moreDetails
Antidepressants may diminish psilocybin’s effects even after discontinuation
Depression

A single dose of psilocybin might help reduce symptoms in treatment-resistant depression

May 12, 2025

A new open-label study suggests that a single dose of psilocybin, combined with psychological support, may reduce symptoms in people with severe treatment-resistant depression. Improvements were sustained for up to 12 weeks, although effects were weaker in those with PTSD.

Read moreDetails
A pill bottle with pills inside
Depression

Common antidepressant may increase pain sensitivity later in life if taken during adolescence

May 11, 2025

A new animal study shows that adolescent use of fluoxetine, a commonly prescribed antidepressant, may have long-lasting effects on how the brain processes pain. Female mice exposed to the drug displayed increased sensitivity to heat stimuli as adults.

Read moreDetails
Psilocybin use has surged in the United States since 2019
Psilocybin

Psilocybin use has surged in the United States since 2019

May 10, 2025

Psilocybin use has surged across the U.S. in recent years, with the biggest increases seen among adults with depression, anxiety, and chronic pain.

Read moreDetails

SUBSCRIBE

Go Ad-Free! Click here to subscribe to PsyPost and support independent science journalism!

STAY CONNECTED

LATEST

What brain scans reveal about the neural correlates of pornography consumption

AI chatbots often misrepresent scientific studies — and newer models may be worse

Is gender-affirming care helping or harming mental health?

Study finds “zombie” neurons in the peripheral nervous system contribute to chronic pain

Therapeutic video game shows promise for post-COVID cognitive recovery

Passive scrolling linked to increased anxiety in teens, study finds

Your bodily awareness guides your morality, new neuroscience study suggests

Where you flirt matters: New research shows setting shapes romantic success

         
       
  • Contact us
  • Privacy policy
  • Terms and Conditions
[Do not sell my information]

Welcome Back!

Login to your account below

Forgotten Password?

Retrieve your password

Please enter your username or email address to reset your password.

Log In

Add New Playlist

Subscribe
  • My Account
  • Cognitive Science Research
  • Mental Health Research
  • Social Psychology Research
  • Drug Research
  • Relationship Research
  • About PsyPost
  • Contact
  • Privacy Policy